IVA Inventiva S.A. Stock Quote

IVA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.37	Insider Own	-	Shs Outstand	40.74M	Perf Week	-1.18%
Market Cap	511.73M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	11.11M	Perf Month	-11.49%
Income	-	PEG	-	EPS next Q	-	Inst Own	12.03%	Short Float	1.65%	Perf Quarter	-10.29%
Sales	5.64M	P/S	90.68	EPS this Y	-	Inst Trans	-	Short Ratio	37.99	Perf Half Y	-15.42%
Book/sh	2.29	P/B	5.49	EPS next Y	-	ROA	-	Target Price	26.46	Perf Year	-33.89%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	10.52 - 19.06	Perf YTD	-8.05%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-34.12%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	19.39%	ATR	0.39
Employees	100	Current Ratio	-	Sales Q/Q	133.50%	Oper. Margin	-	RSI (14)	40.45	Volatility	1.55% 1.77%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.87	Prev Close	12.60
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	4.84K	Price	12.56
Recom	-	SMA20	-3.96%	SMA50	-6.63%	SMA200	-8.05%	Volume	4,221	Change	-0.32%

Mar-08-21

Downgrade

Societe Generale

Buy → Sell

Aug-05-20

Initiated

ROTH Capital

Buy

Aug-04-20

Initiated

Stifel

Buy

$18

Aug-04-20

Initiated

Guggenheim

Buy

$26

Jan-20-22 04:00PM	Inventiva announces participation at several conferences in January and February 2022 GlobeNewswire
Jan-14-22 02:00AM	Half-Year Review of Inventivas Liquidity Contract with Kepler Cheuvreux GlobeNewswire
Dec-16-21 04:00PM	Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-06-21 04:00PM	Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor GlobeNewswire
Nov-10-21 04:00PM	Inventiva reports 2021 Third Quarter Financial Information GlobeNewswire
Nov-03-21 04:00PM	Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting 2021 GlobeNewswire
Oct-29-21 09:29AM	Inventiva announces participation at several conferences in November 2021 GlobeNewswire +5.17%
Oct-28-21 07:15AM	Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022 Benzinga
Oct-27-21 04:00PM	Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes GlobeNewswire
Oct-18-21 04:00PM	Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting 2021 GlobeNewswire
Sep-28-21 04:00PM	Inventiva announces participation at several investor conferences in October 2021 GlobeNewswire
Sep-23-21 02:45AM	Inventiva completes sale of $30 million through its ATM program to existing and new specialized institutional investors GlobeNewswire
Sep-22-21 07:01AM	Fast Track Status Expanded For Inventiva's NASH Treatment Benzinga
Sep-21-21 04:00PM	Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis GlobeNewswire
Sep-20-21 04:10PM	Inventiva reports 2021 first half financial results and provides a corporate update GlobeNewswire
Sep-16-21 04:00PM	Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH GlobeNewswire
Sep-10-21 09:00AM	Inventivas 2021 First-Half Financial Results Presentation GlobeNewswire
Sep-08-21 04:00PM	Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH GlobeNewswire
Aug-30-21 04:00PM	Inventiva announces participation at several investor conferences in September 2021 GlobeNewswire
Aug-02-21 05:00PM	Inventiva announces the implementation of an At-The-Market program in the United States GlobeNewswire
Jul-28-21 04:00PM	Inventiva Reports First-Half of 2021 Financial Information GlobeNewswire
Jul-22-21 10:00AM	Half-Year Review of Inventivas Liquidity Contract with Kepler Cheuvreux GlobeNewswire
Jun-15-21 04:00PM	Inventiva to participate at the SVB Leerink CybeRx Series: Liver Disease Day GlobeNewswire
Jun-09-21 04:00PM	Inventiva announces three scientific presentations at the EASL International Liver Congress 2021 and during a KOL webcast event GlobeNewswire
May-25-21 04:00PM	Inventiva to participate at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-12-21 04:00PM	Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases GlobeNewswire
Apr-26-21 04:00PM	Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit GlobeNewswire
Apr-19-21 04:00PM	Appointment of Martine Zimmermann as Independent Director to Inventivas Board of Directors GlobeNewswire
12:00PM	Results of the votes of the Combined Shareholders Meeting of April 16, 2021 GlobeNewswire
Mar-25-21 01:00PM	Inventiva's Combined Shareholders Meeting of April 16, 2021 - Availability of the preparatory documents and methods for participating and voting GlobeNewswire
10:43AM	Statement of total voting rights and shares forming the companys share capital on March 10th, 2021 GlobeNewswire
Mar-15-21 05:00PM	Inventiva announces filing of its 2020 Universal Registration Document and 2020 Annual Report on Form 20-F GlobeNewswire
Mar-05-21 11:45AM	Inventiva SA to Host Earnings Call ACCESSWIRE
Mar-04-21 04:00PM	2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States GlobeNewswire
Feb-25-21 04:00PM	Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvemen GlobeNewswire
Feb-24-21 04:00PM	Inventiva to participate at several investor conferences in March 2021 GlobeNewswire
Feb-23-21 04:00PM	Inventivas 2020 Full-Year Financial Results Presentation GlobeNewswire -7.64%
Feb-11-21 04:00PM	Full-Year 2020: Cash position and revenues GlobeNewswire
Jan-15-21 11:45AM	Half-Year Review of Inventivas Liquidity Contract with Kepler Cheuvreux GlobeNewswire
Jan-06-21 04:00PM	Inventiva annonce sa participation à la « 39th Annual J.P. Morgan Healthcare Conference » GlobeNewswire
Jan-05-21 04:00PM	Inventiva announces design of Phase III clinical trial with lanifibranor in NASH GlobeNewswire
Dec-07-20 11:18PM	Is IVA A Good Stock To Buy Now? Insider Monkey
04:00PM	Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis GlobeNewswire
Nov-24-20 04:00PM	Inventiva to participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire
Nov-12-20 04:00PM	Q3 2020 Financial Information GlobeNewswire
Nov-10-20 04:00PM	Inventiva receives positive FDA feedback to advance its lead drug candidate lanifibranor into pivotal Phase III in NASH GlobeNewswire
Nov-09-20 04:00PM	Inventiva to participate at the Stifel Virtual Healthcare Conference 2020 and the 11th Jefferies Virtual Healthcare Conference GlobeNewswire
Nov-05-20 04:00PM	Inventiva announces the appointment of Dr. Michael Cooreman as Chief Medical Officer GlobeNewswire
Nov-02-20 04:00PM	Inventiva announces the publication of a scientific paper on the role of PPARs in the treatment of NASH in the medical journal Nature Review Gastroenterology & Hepatology GlobeNewswire
02:00AM	Inventiva announces the additional acceptance of two late-breaking abstracts at the AASLD The Liver Meeting Digital Experience 2020 GlobeNewswire
Oct-28-20 05:00PM	Inventiva to host a Key Opinion Leader webcast from the AASLD The Liver Meeting Digital Experience 2020 GlobeNewswire -7.50%
Oct-19-20 04:00PM	Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci GlobeNewswire
Oct-12-20 04:00PM	Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH GlobeNewswire
Oct-05-20 04:00PM	Inventiva selected to present the results of its NATIVE Phase IIb clinical trial with lanifibranor in NASH during a plenary session at The Liver Meeting Digital Experience 2020 GlobeNewswire
Sep-24-20 12:15PM	Inventiva to participate at several investor conferences in October 2020 GlobeNewswire
Sep-17-20 06:00AM	Inventiva SA to Host Earnings Call ACCESSWIRE +6.94%
Sep-16-20 04:00PM	H1 2020 financial results and corporate business update GlobeNewswire
Sep-09-20 11:45AM	Inventiva to participate at several investor conferences in September 2020 GlobeNewswire
Aug-12-20 11:45AM	Half-Year Review of Inventivas Liquidity Contract with Kepler Cheuvreux GlobeNewswire
Aug-10-20 11:45AM	DESCRIPTION OF THE SHARE BUYBACK PROGRAM & RESUMPTION OF THE LIQUIDITY CONTRACT GlobeNewswire
Jul-24-20 06:12PM	13Ds Filings Barrons.com -5.05%
Jul-15-20 02:40PM	Inventiva announces the closing of $107.7 million initial public offering on the Nasdaq Global Market GlobeNewswire +13.48%
Jul-10-20 08:30AM	Inventiva announces trading resumption of its ordinary shares on Euronext Paris GlobeNewswire
02:00AM	Inventiva announces the pricing of its initial public offering on the Nasdaq Global Market GlobeNewswire
02:00AM	Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris GlobeNewswire

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience